Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark A Hull

Showing results (51-60 of 88) with videos related to

Pageof 9
Sort By:
BMC Cancer|February 28, 2013
Regional differences in prostaglandin E₂ metabolism in human colorectal cancer liver metastasesAlastair L Young, Claire R Chalmers, Gillian Hawcroft, et al.
Alimentary Pharmacology & Therapeutics|August 12, 2025
Systematic Review: The Relationship Between the Faecal Microbiome and Colorectal Neoplasia in Shotgun Metagenomic StudiesSarah Manning, Eleanor Hackney, Yashvee Dunneram, et al.
Gut|June 20, 2024
Long-term stability of the faecal microbiome profile in faecal immunochemical test (FIT) samplesSuparna Mitra, Christopher J Stewart, Andrew Nelson, et al.
Gut|January 29, 2014
Anticolorectal cancer activity of the omega-3 polyunsaturated fatty acid eicosapentaenoic acidAndrew J Cockbain, Milene Volpato, Amanda D Race, et al.
Gut|May 21, 2020
Using faecal immunochemical test (FIT) undertaken in a national screening programme for large-scale gut microbiota analysisAndrea C Masi, Sara Koo, Christopher A Lamb, et al.
Trials|July 31, 2013
A randomized controlled trial of eicosapentaenoic acid and/or aspirin for colorectal adenoma prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme (The seAFOod Polyp Prevention Trial): study protocol for a randomized controlled trialMark A Hull, Anna C Sandell, Alan A Montgomery, et al.
Genes & Nutrition|May 14, 2026
The relationship between elongation of very long-chain fatty acids (ELOVL) 2 polymorphism rs953413 and blood n-3 HUFA levels: a secondary analysis of EPA treatment in the seAFOod polyp prevention trialGe Sun, John R Davies, Tracey Mell, et al.
Alimentary Pharmacology & Therapeutics|July 31, 2023
Colorectal polyp outcomes after participation in the seAFOod polyp prevention trial: Evidence of rebound elevated colorectal polyp risk after short-term aspirin useAmy Downing, Hayley Fenton, Claire Nickerson, et al.
Cancer Prevention Research (Philadelphia, Pa.)|November 16, 2011
Aspirin in the chemoprevention of colorectal neoplasia: an overviewAndrew T Chan, Nadir Arber, John Burn, et al.
The Journal of Nutrition|December 15, 2024
The Relationship Between Dietary and Supplemental omega-3 Highly Unsaturated Fatty Acid Intake, Blood and Tissue omega-3 Highly Unsaturated Fatty Acid Concentrations, and Colorectal Polyp Recurrence: A Secondary Analysis of the seAFOod Polyp Prevention TrialGe Sun, Harriett Fuller, Hayley Fenton, et al.
Pageof 9

Showing results (51-60 of 88) with videos related to

Sort By:
Pageof 9
BMC Cancer|February 28, 2013
Regional differences in prostaglandin E₂ metabolism in human colorectal cancer liver metastasesAlastair L Young, Claire R Chalmers, Gillian Hawcroft, et al.
Alimentary Pharmacology & Therapeutics|August 12, 2025
Systematic Review: The Relationship Between the Faecal Microbiome and Colorectal Neoplasia in Shotgun Metagenomic StudiesSarah Manning, Eleanor Hackney, Yashvee Dunneram, et al.
Gut|June 20, 2024
Long-term stability of the faecal microbiome profile in faecal immunochemical test (FIT) samplesSuparna Mitra, Christopher J Stewart, Andrew Nelson, et al.
Gut|January 29, 2014
Anticolorectal cancer activity of the omega-3 polyunsaturated fatty acid eicosapentaenoic acidAndrew J Cockbain, Milene Volpato, Amanda D Race, et al.
Gut|May 21, 2020
Using faecal immunochemical test (FIT) undertaken in a national screening programme for large-scale gut microbiota analysisAndrea C Masi, Sara Koo, Christopher A Lamb, et al.
Trials|July 31, 2013
A randomized controlled trial of eicosapentaenoic acid and/or aspirin for colorectal adenoma prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme (The seAFOod Polyp Prevention Trial): study protocol for a randomized controlled trialMark A Hull, Anna C Sandell, Alan A Montgomery, et al.
Genes & Nutrition|May 14, 2026
The relationship between elongation of very long-chain fatty acids (ELOVL) 2 polymorphism rs953413 and blood n-3 HUFA levels: a secondary analysis of EPA treatment in the seAFOod polyp prevention trialGe Sun, John R Davies, Tracey Mell, et al.
Alimentary Pharmacology & Therapeutics|July 31, 2023
Colorectal polyp outcomes after participation in the seAFOod polyp prevention trial: Evidence of rebound elevated colorectal polyp risk after short-term aspirin useAmy Downing, Hayley Fenton, Claire Nickerson, et al.
Cancer Prevention Research (Philadelphia, Pa.)|November 16, 2011
Aspirin in the chemoprevention of colorectal neoplasia: an overviewAndrew T Chan, Nadir Arber, John Burn, et al.
The Journal of Nutrition|December 15, 2024
The Relationship Between Dietary and Supplemental omega-3 Highly Unsaturated Fatty Acid Intake, Blood and Tissue omega-3 Highly Unsaturated Fatty Acid Concentrations, and Colorectal Polyp Recurrence: A Secondary Analysis of the seAFOod Polyp Prevention TrialGe Sun, Harriett Fuller, Hayley Fenton, et al.
Pageof 9